BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• Genetown

  Aura Biosciences to Participate at the 11th Annual SVB Leerink Global Healthcare Conference

  Aura Biosciences to Participate at the 11th Annual SVB Leerink Global Healthcare Conference.

  February 9, 2022

   · 

  1 min read
• Biotech Bay

  INVO Bioscience Eyes +20 U.S. Cities To Expand Rollout Of Advanced Infertility Treatment ‘INVO Centers’

  Today, the global fertility market is a multi-billion industry, yet remains severely underserved, with estimates suggesting more than 90% of couples in need of infertility treatment going without care.

  February 9, 2022

   · 

  2 min read
• Business

  Invitation to Conference Call Regarding Promore Pharma’s Year-end Report 2021

  Promore Pharma publishes its Year-end Report 2021 in the morning of 16 February 2022.

  February 9, 2022

   · 

  2 min read
• Lone Star Bio

  Genprex to Present at Upcoming Investor Conferences Highlighting its Gene Therapies for Cancer and Diabetes

  Genprex, Inc. announced that its President and Chief Executive Officer, Rodney Varner, will provide an overview of the Company’s gene therapies for cancer and diabetes to investors at the 2022 BIO CEO and Investor Conference and at the 2022 Diamond Equity Research Conference.

  February 9, 2022

   · 

  5 min read
• BioForest

  Aptevo Therapeutics Earns $10 Million Non-Dilutive Milestone Payment on Sales of RUXIENCE, Provides Company Update

  Aptevo Therapeutics Inc. today announced that the Company has earned a $10 million non-dilutive milestone payment related to 2021 sales of RUXIENCE®.

  February 9, 2022

   · 

  9 min read
• Business

  AiCuris and Hybridize Therapeutics Enter Worldwide License Agreement of up to €100M for a Direct-Acting RNA-Based Therapy Against BK Virus

  AiCuris acquires exclusive rights to develop and commercialize Hybridize’s program to prevent severe disease from BK virus (BKV) infections in immunocompromised patients.

  February 9, 2022

   · 

  7 min read
• Genetown

  Wave Life Sciences to Present at the Virtual 11th Annual SVB Leerink Global Healthcare Conference 2022

  Wave Life Sciences Ltd. announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Virtual 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16, 2022 at 10:40 a.m. ET.

  February 9, 2022

   · 

  1 min read
• Business

  Akebia Therapeutics to Report Fourth Quarter and Full-Year 2021 Financial Results and Discuss Recent Business Highlights

  Akebia Therapeutics, Inc. today announced plans to release its financial results for the fourth quarter and full-year 2021 ended December 31, 2021 , on Tuesday, March 1 , 2022.

  February 9, 2022

   · 

  3 min read
• Biotech Bay

  BioMarin Sells Priority Review Voucher for $110 Million

  BioMarin Pharmaceutical Inc. announced that it has entered into a definitive agreement with an undisclosed purchaser to sell the Rare Pediatric Disease Priority Review Voucher it obtained in November 2021 for a lump sum payment of $110,000,000.

  February 9, 2022

   · 

  4 min read
• Biotech Bay

  Mirum Pharmaceuticals to Present at SVB Leerink 11th Annual Global Healthcare Conference

  Mirum Pharmaceuticals, Inc. announced that it will present during the SVB Leerink 11th Annual Global Healthcare Conference taking place virtually February 14-18, 2022.

  February 9, 2022

   · 

  1 min read